C₂N collaborates with some of the leading researchers in the world to better understand the causes of Alzheimer’s disease as well as ways to better diagnose and treat it. C₂N also works with cutting edge pharmaceutical companies seeking to develop new therapies that will reverse or prevent neurodegeneration.

About Partnership Opportunities

Pipeline and Services

Diagnostics – C₂N is presently developing diagnostic tests intended to aid in the early diagnosis and more effective treatment of Alzheimer’s disease. Specifically, C₂N’s research efforts are focused on four main areas:

Detecting Alzheimer’s disease pathology at its earliest stages;
Monitoring the progression of Alzheimer’s disease pathology;
Tracking a patient’s biological response to Alzheimer’s disease treatments;
Helping to distinguish Alzheimer’s disease from other forms of neurodegeneration, each of which can cause memory and thinking issues, or other impairments of function

These tests are all based on the company’s proprietary SISAQ™ method that measures the absolute abundance of proteins and other biomolecules as well as the metabolism of such markers in biological samples.

Contract Research Services – C₂N is leading ways to provide new insights into the molecular mechanisms of brain diseases and measure the biologic activity of emerging therapies. While C₂N primarily focuses on clinical diagnostic efforts for Alzheimer’s disease, the company’s contract research services address multiple neurological diseases and services beyond diagnostic assays.

Our Partners

C₂N is grateful to the patients, government agencies, academic centers, foundations, non-profit organizations, and company collaborators that have supported the development of the PrecivityAD® blood test.

Government Agencies & Academic Centers

C₂N Diagnostics works with multiple academic centers to test new scientific ideas and provide important contributions to the field.

NIA, one of the 27 Institutes and Centers of NIH, leads a broad scientific effort to understand the nature of aging and to extend the healthy, active years of life. NIA is the primary Federal agency supporting and conducting Alzheimer's disease research.

The Knight Alzheimer’s Disease Research Center at Washington University in St. Louis has provided foundational support in the development of the PrecivityAD® blood test. C₂N Diagnostics was formed in 2007 by scientific co-founders Drs. David Holtzman and Randall Bateman of Washington University School of Medicine. Since that time, the Knight ADRC has provided extensive research collaboration and support for a variety of scientific studies.

Bateman and Holtzman Laboratories, Department of Neurology at the Washington University School of Medicine in St. Louis

The Bateman and Holtzman laboratories investigate the causes and methods of diagnosis and treatment of Alzheimer’s disease (AD) using a variety of innovative methods and techniques. Since C₂N’s inception, the laboratories have been important collaborators and contributed to the development of intellectual property that is part of the PrecivityAD® test and other commercial technologies available at C₂N.

https://neuro.wustl.edu/labs/bateman_r

https://neuro.wustl.edu/labs/holtzman_d/

Foundations & Non-profit Organizations

C₂N Diagnostics partners with leading disease research foundations to bridge critical translational gaps in funding and science. These foundations provide generous capital resources, domain knowledge, and community networks to accelerate C₂N’s efforts.